Novartis’ Shaw Pushing For U.S. Outcomes-Based Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Country Head Christi Shaw talked in an interview about Novartis’ near-term growth drivers – namely the heart failure drug LCZ696 – and how Novartis is evaluating outcomes-based reimbursement models to address growing payer pressure in the U.S.
You may also be interested in...
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.
Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK
Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.